Molecular Devices’ stock lost 16.9 percent of its value for the trading week ended Tuesday, following last week’s announcement that it was lowering its revenue guidance for the third quarter (see related article). The firm led all eight decliners for the trading period. Meanwhile, Stratagene shares gained 10.7 percent to lead all issues in the BCW Index.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.